DOUBLE-BLIND TRIAL OF SYNTHETIC SALMON-CALCITONIN IN THE TREATMENT OF ACUTE-PANCREATITIS

被引：68

作者：

GOEBELL, H

AMMANN, R

HERFARTH, C

HORN, J

HOTZ, J

KNOBLAUCH, M

SCHMID, M

JAEGER, M

AKOVBIANTZ, A

LINDER, E

ABT, K

NUESCH, E

BARTH, E

机构：

[1] WAIDHOSP,DEPT MED,ZURICH,SWITZERLAND

[2] WAIDHOSP,DEPT SURG,ZURICH,SWITZERLAND

[3] UNIV ULM,DEPT SURG,D-7900 ULM,FED REP GER

[4] SANDOZ LTD,DIV MED,CH-4002 BASEL,SWITZERLAND

[5] UNIV FRANKFURT,SCH MED,DEPT BIOMATH,D-6000 FRANKFURT 70,FED REP GER

[6] UNIV ZURICH HOSP,DEPT MED,ZURICH,SWITZERLAND

[7] UNIV ZURICH HOSP,DEPT SURG,ZURICH,SWITZERLAND

来源：

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | 1979年 / 14卷 / 07期

关键词：

Acute pancreatitis; mortality; Double-blind trial; Salmon calcitonin;

D O I：

10.3109/00365527909181420

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A multicenter randomized double-blind trial on the use of synthetic salmon calcitonin (SCT) was carried out in 94 patients with acute pancreatitis. In addition to strict standard treatment - without aprotinin, atropine, or antacids - 50 patients received daily 3 × 20 μg = 300 MRCU SCT intravenously and 44 patients received placebo for 6 days. Mortality rate was not influenced, overall mortality being 5.3% The number of patients without pain and with normalized serum amylase on a given day was significantly higher in the group treated with SCT. Other parameters such as doses of analgesics, leukocyte count, and normalization of seven defined clinical and laboratory criteria within 6 days showed a positive trend without reaching significance. © 1979 Informa UK Ltd.

引用

页码：881 / 889

页数：9